Default company panoramic image

NeuMedics Inc.

NeuMedics is developing a topical formulation that can be used to treat Diabetic Macular Edema (DME), Trauma and Uveitis all are large unmet medical needs

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, US
  • Currency USD
  • Founded August 2008
  • Employees 3
  • Incorporation Type C-corp
  • Website

Company Summary

NeuMedics has developed anti-inflammatory compounds that also have anti VEGF properties. They are being developed for topical delivery to the eye for treatment of DME. DME is the leading cause of blindness for up to 2.5 million diabetic patients in U.S.; 75,000 new cases each year in U.S. Treatment for patients suffering from this disease are limited to expensive Biologic drugs or steroids and require frequent direct injections into the eye.


  • Default avatar
    Iain Duncan

    Sixteen years in small and startup pharma in executive positions and 20 years in various fortune 50 Corporations.VP Manufacturing and Supply Chain Operations, Horizon Therapeutics with responsibility for Product Development, Manufacturing, Quality Control, Distribution and Logistics functions. Mr Duncan formulated and developed Horizons’ lead product, DUEXIS© (patent pending). Co- founder of NeuMedics, co founder of Corus Pharma Inc.

  • Default avatar
    William Schwieterman M.D.,CMO
    VP and Chief Medical Officer

    Expert in the clinical development of a wide range of investigational therapeutic agent and spent 10 years as a Supervisor at the FDA and as a clinical reviewer on numerous biological and pharmaceutical-based agents including Enbrel, Remicade, Pegasys, Xigris and Zenapax, and has written numerous FDA guidance documents. Dr Schwieterman is a board-certified internist and a rheumatologist.

  • Default avatar
    Carl Osborne, D.V.M.
    V.P. of Development

    Over 19 years of experience in all phases of drug development and commercialization.Dr Osborne is veterinarian, toxicologist, and former FDA compliance officer and has been involved in the development of over 350 products world-wide.

  • Default avatar
    Barbara Wirostko,M.D.
    Scientific Advisor and Co-founder

    A board-certified ophthalmologist and a fellow of the American Academy of Ophthalmology, Dr. Wirostko maintains an academic research and clinical practice with the University of Utah's Moran Eye Center as a Clinical Adjunct Associate Professor in Ophthalmology. She is a former Development Lead at Pfizer, where she led a successful EU regulatory EMA filing for Xalatan in pediatric glaucoma. She has also served as CMO at Altheos Inc.


  • Default avatar
    Johnston Law Firm, PLLC
    Default avatar
    White Thompson & Co., PS
    Default avatar
    Dr Sophie Bakri
    Scientific Advisor